Drug intelligence / Profile preview

UCB3101

Development stage: Unknown
Lead developer: UCB

Overview

UCB3101 is an investigational drug developed by UCB Biopharma. It is a new molecular entity currently in phase 1 clinical trials for an undisclosed indication. The first-in-human studies are evaluating the safety, tolerability, and pharmacokinetics of single ascending doses in healthy volunteers. As of now, the specific mechanism of action and therapeutic target have not been disclosed publicly[2][3][4][8].

Other names: UCB 3101UCB3101UCB-3101

Beyond the preview

Go deeper on UCB3101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UCB3101.

Explore the full profile